Core Insights - Teleflex Incorporated has published its 2024 Global Impact Report, highlighting its achievements and future goals in Corporate Social Responsibility (CSR) [1][2] - The report aligns with major sustainability frameworks including the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD) [1] CSR Pillars - The 2024 Global Impact Report details accomplishments and future plans across four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance [2] Key Highlights - The report showcases Teleflex's ongoing commitment to CSR and the recognition it has gained among stakeholders, reflecting the pride of employees in the company's impact on the planet and society [2] - Teleflex has conducted a double materiality assessment in line with the E.U. Corporate Sustainability Reporting Directive to ensure its CSR strategy remains relevant [7] - The company has committed to the World Economic Forum Zero Health Gaps Pledge, aiming for equitable access to healthcare [7] - In 2024, Teleflex achieved ISO 14001 certification for 6 sites and plans to expand this certification in the future [7]

Core Insights - Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System's advantages over Rezūm and tamsulosin in terms of early patient satisfaction, rapid symptom relief, and sexual function outcomes [2][3] Group 1: UroLift™ System Findings - The UroLift™ System demonstrated significantly higher patient satisfaction at two weeks and one month post-treatment compared to Rezūm, with shorter catheterization times and improved symptom relief [5] - At three months, patients treated with the UroLift™ System showed significantly better symptom improvement and sexual function outcomes compared to those on tamsulosin, with 70% of men on medication opting to switch to UroLift™ [5] - Real-world data from the American Urological Association Quality Registry (AQUA) confirmed that BPH drugs provide limited improvement, while the UroLift™ System offers rapid symptom score improvement at three months [5] Group 2: Safety of Stabilized Hyaluronic Acid (sHA) - The study confirmed the safety of stabilized hyaluronic acid as a rectal spacer, showing a low incidence of rectal wall infiltration and no severe complications, reinforcing its use during prostate cancer treatment [4][5] - The sHA rectal spacer allows for individualized spacing and is effective in protecting patients during radiation therapy, with a focus on its reversibility as a clinical advantage [4]

Summary of Teleflex Conference Call Company Overview - **Company**: Teleflex - **Industry**: Medical Technology Q1 Results - **Growth Performance**: Q1 growth was reported at -3.8%, adjusted for two less selling days, the growth was approximately -1.7% [3][4] - **Product Performance**: Strong performance noted in balloon pumps in The Americas and progress with Pallet and Baragel products [3][4] - **OEM Challenges**: OEM segment experienced negative growth due to a lost customer costing approximately $7 million and inventory management issues among key customers [5][6] Guidance and Growth Expectations - **Full Year Guidance**: Reiterated guidance of 1% to 2% growth for the year, with expectations of acceleration in the second half [7][10] - **Quarterly Projections**: Anticipated growth of 1% in Q2, 3.5% in Q3, and 6% in Q4, with a significant pickup expected due to the anniversary of the lost customer and additional selling days in Q4 [7][8][10] Tariff Impact - **Tariff Guidance**: Total tariff impact estimated at $55 million, with 50% attributed to China. The company is hopeful for exemptions for medical devices [11][13][15] - **Mitigation Strategies**: Strategies include improving USMCA compliance, pricing adjustments, and supply chain changes to mitigate tariff impacts [20][21] Business Separation Strategy - **Separation Rationale**: Decision to separate into two entities based on different capital allocation and growth strategies, aiming to unlock shareholder value [25][26] - **Growth Profiles**: One entity expected to grow at low single digits with mid-fifties gross margins, while Teleflex RemainCo projected to grow at over 6% with mid-sixties gross margins [27][28] Market Dynamics - **OEM Business Outlook**: Anticipated negative growth of 10-12% for the OEM segment in 2025, but expected to return to growth in 2026 [35][36] - **UroLift Challenges**: UroLift has faced pressure due to reimbursement changes, but improvements are expected as the reimbursement environment stabilizes [37][38] Acquisition Interest - **Interest in NewCo**: Significant inbound interest in NewCo assets from both financial and strategic parties, indicating strong market validation [41][42] - **Sale vs. Spin**: The decision on whether to sell or spin off NewCo will be based on what maximizes shareholder value [43][46] Product Performance Highlights - **Pallet Growth**: Pallet product grew approximately 30% in the previous year and continues to trend above initial growth expectations [59][60] - **Baragel Market Expansion**: Anticipated market expansion for Baragel with a new indication for post-radical prostatectomy spacing expected by the end of 2026, potentially adding $100 million to the addressable market [61][63][64] Conclusion - Teleflex is navigating a challenging environment with strategic adjustments in response to market dynamics, tariff impacts, and a focus on unlocking shareholder value through business separation and product innovation.

Core Insights - The Titan SGS™ Stapler is associated with significantly lower rates of postoperative gastroesophageal reflux disease (GERD) and shorter hospital stays compared to traditional multi-fire staplers in robotic-assisted laparoscopic sleeve gastrectomy (LSG) procedures [1][3][4] - A retrospective analysis of 257 patients showed that at one year post-procedure, 7.1% of patients using the Titan SGS™ Stapler reported GERD, compared to 26.4% in the multi-fire cohort [3][4] - The study highlights the importance of consistent surgical techniques in achieving better patient outcomes, particularly in reducing GERD incidence [2][3] Company Overview - Teleflex Incorporated is a leading global provider of medical technologies, focusing on improving health and quality of life through innovative solutions [5][6] - The Titan SGS™ Stapler is the first single-fire surgical stapler specifically designed for sleeve gastrectomy pouch creation, featuring a 23cm staple line for improved surgical outcomes [3][4] - The company aims to enhance the adoption of bariatric surgery by addressing common postoperative complications such as GERD [3][5]

Teleflex Incorporated (TFX) posted first-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $2.91, down 9.3% from the year-ago quarter's figure. The metric topped the Zacks Consensus Estimate by 1%. GAAP EPS was $2.07 compared with $0.33 in the prior-year period. Following the announcement, shares of the company rose 0.4% last Friday. TFX's Revenues Net revenues fell 5% year over year (down 3.8% at constant exchange rate or CER) to $700.7 million. However, the metric surpassed the ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Teleflex Incorporated due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a significant drop in Teleflex's stock price, which fell by 21.6% on February 27, 2025, following the announcement of a company split and a €760 million deal with Biotronik [3]. - Shareholders who purchased Teleflex securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the number of settlements since 2013 [4].

NEW YORK, May 1, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th ...

LOS ANGELES, May 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or "the Company") (NYSE: TFX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teleflex is the subject of an article published by Fierce Biotech on February 27 ...

For the quarter ended March 2025, Teleflex (TFX) reported revenue of $700.67 million, down 5% over the same period last year. EPS came in at $2.91, compared to $3.21 in the year-ago quarter.The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $699.13 million. With the consensus EPS estimate being $2.88, the EPS surprise was +1.04%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Financial Data and Key Metrics Changes - For Q1 2025, Teleflex reported revenues of $700.7 million, a decrease of 5% year over year on a GAAP basis and a decline of 3.8% on an adjusted constant currency basis, which was within the guidance range of -3% to -4% [5][27] - Adjusted earnings per share (EPS) for the first quarter was $2.91, reflecting a 9.3% decrease year over year [5][25] - Adjusted gross margin was 60.4%, a 70 basis point decrease compared to the prior year, primarily due to cost inflation and unfavorable product mix [23] - Adjusted operating margin was 24.7%, a decline of 190 basis points year over year [23] Business Line Data and Key Metrics Changes - **Americas**: Revenues were $475.7 million, a 3.2% decrease year over year, impacted by OEM declines and challenges in the UroLift office site [6][7] - **EMEA**: Revenues decreased by 2.8% year over year to $151.2 million, with strong performance in Surgical and Vascular Access offset by anesthesia [8] - **Asia**: Revenues were $73.8 million, a 9.7% decrease year over year, in line with expectations due to volume-based procurement in China [9] - **Vascular Access**: Revenue increased by 1.9% year over year to $182.4 million, driven by growth in PICCs [9] - **Interventional**: Revenue was $137.5 million, an increase of 3.2% year over year, led by growth in complex catheters [10] - **Anesthesia**: Revenue decreased by 8.6% year over year to $86.6 million, impacted by tough comps in military orders [11] - **Surgical**: Revenue increased by 2% year over year to $105.8 million, with solid underlying trends [12] - **OEM**: Revenue decreased by 26.8% year over year to $63.9 million, primarily due to a lost customer contract [12] Market Data and Key Metrics Changes - The company experienced softness in orders in EMEA during Q1, which has since recovered in April [5] - The Asia market faced challenges due to volume-based procurement, but sequential quarterly revenue improvement is expected through the remainder of 2025 [9] Company Strategy and Development Direction - Teleflex announced plans to separate into two independent publicly traded companies to enhance shareholder value, with significant inbound interest in acquiring NewCo [18][19] - The acquisition of BioTronix's Vascular Intervention business is on track to close by the end of Q3 2025, expected to enhance Teleflex's portfolio in the cath lab [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the headwinds faced in Q1, including OEM business pressures and UroLift declines, are expected to be transitory [35] - The company anticipates sequential improvement in revenue from China and expects to navigate tariff impacts through various mitigation strategies [30][31] Other Important Information - The company has initiated an accelerated share repurchase program, completing it in April 2025, which returned capital to shareholders [26] - The updated financial guidance for 2025 includes adjusted constant currency revenue growth expectations of 1% to 2% and adjusted EPS in the range of $13.2 to $13.6 [27][31] Q&A Session Summary Question: Has there been any incremental demand on the OEM side of the business? - Management noted a pickup in demand within the OEM business as the quarter progressed, indicating base demand rather than supply chain issues [42][43] Question: Can you provide more details on the $55 million tariff impact? - The $55 million figure reflects current tariffs and does not include any mitigation strategies. Management is exploring various strategies to mitigate tariff impacts [47][49] Question: What is the interest level in NewCo? - There is significant interest in NewCo, with a healthy mix of both strategic and private equity interest, and the company is open to exploring all options to maximize shareholder value [60][76] Question: How will tariffs impact RemainCo and SpinCo? - Management indicated that tariffs will impact both entities, but specifics will be discussed closer to the separation date [82] Question: What are the early views on cost and revenue synergies from BioTronix? - The focus will be on leveraging the BioTronix channel in Europe and the Teleflex channel in the Americas to drive revenue growth [84]